Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials-Reference-Cited by-同舟云学术

Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials

Published:2018-01-16 Issue:4 Volume:47 Page:259-269
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Brahe CH¹²³,Dehlendorff C⁴,Østergaard M¹²³,Johansen JS²⁵,Ørnbjerg LM¹³,Hørslev-Petersen K⁶,Stengaard-Pedersen K⁷,Junker P⁸,Ellingsen T⁹,Lindegaard H⁸,Hansen I¹⁰,Lottenburger T¹¹,Jacobsen S¹,Jurik AG¹²,Hetland ML¹²³

Affiliation:

1. Copenhagen Center for Arthritis Research (COPECARE), Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark

2. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

3. DANBIO Registry, Centre for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark

4. Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark

5. Department of Medicine and Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark

6. King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Gråsten, Denmark

7. Department of Rheumatology, Aarhus University Hospital and lnstitute of Clinical Medicine, Aarhus University, Aarhus, Denmark

8. Department of Rheumatology, Odense University Hospital, Odense, Denmark

9. Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark

10. Department of Rheumatology, Viborg Regional Hospital, Viborg, Denmark

11. Department of Medicine, Vejle Regional Hospital, Vejle, Denmark

12. Department of Radiology, Aarhus University Hospital and Institute of Clinical Medicine, Aarhus University, Aarhus, Denmark

Funder

Gigtforeningen

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2017.1376107

Reference36 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

2. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis

3. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort

4. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate

5. Meta-analysis: Diagnostic Accuracy of Anti–Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in metabolic parameters and serum YKL-40 levels in Chinese rheumatoid arthritis patients during tocilizumab therapy;Clinical Rheumatology;2024-05-02

2. Is there a paradoxical side effect? Is it a case of inefficiency? Peripheral ulcerative keratitis in a patient with rheumatoid arthritis in remission treated with tocilizumab;TURK J PH MED REHAB;2024

3. YKL-40 as a biomarker in various inflammatory diseases;Biochemia medica;2023-12-15

4. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis;RMD Open;2023-04

5. Develop companion radiopharmaceutical YKL40 antibodies as potential theranostic agents for epithelial ovarian cancer;Biomedicine & Pharmacotherapy;2022-11